Susan Galbraith, AstraZeneca EVP of oncology R&D (Rachel Kiki for Endpoints News)

As­traZeneca push­es Tagris­so-chemo com­bo fol­low­ing pos­i­tive pro­gres­sion-free sur­vival da­ta

As­traZeneca’s EGFR in­hibitor Tagris­so (os­imer­tinib) could be on its way to adding an­oth­er lung can­cer in­di­ca­tion af­ter the com­pa­ny said on Tues­day the drug plus chemo showed sta­tis­ti­cal­ly sig­nif­i­cant and clin­i­cal­ly mean­ing­ful im­prove­ment in pro­gres­sion-free sur­vival com­pared to Tagris­so as a monother­a­py in late-stage lung can­cer pa­tients.

In the Phase III FLAU­RA2 tri­al, As­traZeneca test­ed out a Tagris­so-chemo com­bo in late-stage pa­tients with lo­cal­ly ad­vanced or metasta­t­ic EGFR-mu­tat­ed non-small cell lung can­cer (NSCLC). Though no da­ta were pro­vid­ed, the pri­ma­ry end­point, pro­gres­sion-free sur­vival, was sta­tis­ti­cal­ly sig­nif­i­cant, ac­cord­ing to As­traZeneca.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.